Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection
Edaravone, the first known free radical scavenger, has demonstrated cellular protective properties in animals and humans. Owing to its antioxidant activity, edaravone modulates oxidative damage in various diseases, especially neurodegenerative diseases. In 2015, edaravone was approved in Japan to tr...
المؤلفون الرئيسيون: | Sun Joo Cha, Kiyoung Kim |
---|---|
التنسيق: | مقال |
اللغة: | English |
منشور في: |
MDPI AG
2022-01-01
|
سلاسل: | Antioxidants |
الموضوعات: | |
الوصول للمادة أونلاين: | https://www.mdpi.com/2076-3921/11/2/195 |
مواد مشابهة
-
A New Treatment Option for Amyotrophic Lateral Sclerosis: Edaravone
حسب: Erdi Şahin
منشور في: (2018-03-01) -
Edaravone: A new hope for patients with amyotrophic lateral sclerosis
حسب: Shivangi Garg, وآخرون
منشور في: (2019-01-01) -
Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan
حسب: Hideki Houzen, وآخرون
منشور في: (2021-07-01) -
Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
حسب: Jin-Mo Park, وآخرون
منشور في: (2022-07-01) -
Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis
حسب: Chang Liu, وآخرون
منشور في: (2024-10-01)